| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Inactive control for c-Jun N-terminal kinase (JNK). D-JBD19 is an impermeable peptide that serves as an inactive control for the JNK inhibitor D-JNK11. The active D-JNK11 peptide inhibits the interaction of JNK with its substrate c-Jun, blocking the JNK signaling pathway. D-JBD19 is either non-permeable or lacks the specific residues to inhibit JNK, making it a negative control to account for non-specific peptide effects, ensuring that any observed neuroprotection is due to JNK inhibition.
|
|---|---|
| ln Vitro |
In accordance with the dJNKi peptide, D-JBD19 is a non-permeable cargo [1].
In vitro, D-JBD19 is a non-permeable cargo corresponding to the dJNKi peptide. Unlike the active D-JNK11, D-JBD19 cannot cross the cell membrane efficiently. Therefore, when applied to cultured neurons or cell lines, it should not affect intracellular JNK signaling or downstream targets (e.g., c-Jun phosphorylation). It serves as a negative control to ensure that the effects seen with D-JNK11 are due to intracellular JNK inhibition. |
| ln Vivo |
Neuroprotective effect of D-JBD19 on middle cerebral artery occlusion (MCAO) compared with D-JNKI1. Immediately after ischemia, 15.7 ng of D-JBD19 or D-JNKI1 or 1570 ng of D-JBD19 was given intravenously. The animals were sacrificed after 24 hours. 100 times more D-JBD19 than D-JNKI1[2] is required to give protection.
In a rat model of middle cerebral artery occlusion (MCAO, a model of stroke), 15.7 ng of D-JBD19 injected intracerebroventricularly (i.c.v.) immediately after ischemia does not provide significant neuroprotection. In contrast, 100 times more D-JBD19 (1570 ng) is needed to provide a level of protection equivalent to the active D-JNK11 (15.7 ng). This 100-fold difference in potency demonstrates the specificity of JNK inhibition for neuroprotection. |
| Enzyme Assay |
A cell-free ELISA-based peptide uptake assay is used to assess membrane permeability. Liposomes are prepared to mimic the cell membrane. Biotinylated D-JBD19 or D-JNK11 is incubated with the liposomes. Unbound peptide is washed away. The amount of bound peptide is quantified by adding streptavidin-HRP and a chemiluminescent substrate. D-JBD19 will show significantly reduced binding to the liposomes compared to the active, cell-permeable control.
|
| Cell Assay |
Primary cortical neurons are isolated from embryonic day 18 (E18) rat embryos. Cells are seeded in 24-well plates and allowed to mature for 10 days in vitro. The medium is replaced with serum-free medium for 1 hour. Then, 15.7 ng of D-JBD19 or D-JNK11 is added. Cultures are treated with an excitotoxic stimulus (e.g., 100 microM NMDA for 10 minutes) 1 hour later. After 24 hours, cell viability is measured using an MTT assay.
|
| Animal Protocol |
Adult male Sprague-Dawley rats (250-300 g) are anesthetized, and the MCAO model is performed using an intraluminal filament for 60 minutes. In a stereotaxic apparatus, a 30-gauge needle is inserted into the left lateral ventricle (i.c.v.). Immediately after reperfusion, D-JBD19 (15.7 ng or 1570 ng) is injected in a total volume of 5 uL of vehicle (e.g., PBS). The needle is left in place for 5 minutes. After 24 hours, the animals are sacrificed, and brain sections are stained with TTC to quantify the infarct volume.
|
| ADME/Pharmacokinetics |
As a peptide, D-JBD19 is likely rapidly degraded by proteases in the blood and tissues when administered systemically, which is why it is typically administered directly into the brain (i.c.v.) for CNS research. Its half-life in cerebrospinal fluid (CSF) is likely short (minutes to hours). It is not orally available and is generally unstable in plasma unless specially formulated. The molecular weight is ~2250.56 g/mol.
|
| Toxicity/Toxicokinetics |
There is no evidence that the 15.7 ng dose of D-JBD19 causes any neurotoxicity or adverse effects when injected into the brain. The compound is used as a control specifically because it lacks the pharmacological activity of the active peptide. At very high doses (100-fold higher than the effective dose of the active peptide), D-JBD19 begins to show non-specific neuroprotective effects, indicating the upper limit of the control window. No routine toxicity has been reported.
|
| References | |
| Additional Infomation |
D-JBD19 is a research-grade peptide used exclusively as an inactive control. It is not a drug candidate and has no therapeutic use or clinical trial history. It is essential for target deconvolution and validating preclinical studies involving D-JNK11, a known neuroprotective agent. It is often used in studies of stroke, traumatic brain injury (TBI), and neurodegenerative diseases where the JNK pathway is involved.
|
| Molecular Formula |
C99H164N32O28
|
|---|---|
| Molecular Weight |
2250.55908107758
|
| Exact Mass |
2250.242
|
| CAS # |
954134-42-0
|
| PubChem CID |
146026286
|
| Sequence |
Asp-Gln-Ser-Arg-Pro-Val-Gln-Pro-Phe-Leu-Asn-Leu-Thr-Thr-Pro-Arg-Lys-Pro-Arg
|
| SequenceShortening |
DQSRPVQPFLNLTTPRKPR
|
| Appearance |
White to off-white solid powder
|
| LogP |
-13.1
|
| Hydrogen Bond Donor Count |
33
|
| Hydrogen Bond Acceptor Count |
33
|
| Rotatable Bond Count |
72
|
| Heavy Atom Count |
159
|
| Complexity |
5030
|
| Defined Atom Stereocenter Count |
21
|
| SMILES |
C([C@H]1CCCN1C(=O)[C@@H](CCC(=O)N)NC(=O)[C@@H](C(C)C)NC([C@H]1CCCN1C(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CO)NC(=O)[C@@H](CCC(=O)N)NC(=O)[C@H](N)CC(=O)O)=O)(=O)N[C@@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(=O)N)C(=O)N[C@H](CC(C)C)C(=O)N[C@H]([C@@H](O)C)C(=O)N[C@H]([C@@H](O)C)C(N1CCC[C@@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCCN)C(N1CCC[C@@H]1C(=O)N[C@@H](C(=O)O)CCCNC(N)=N)=O)=O)CC1C=CC=CC=1
|
| InChi Key |
IPZJMEJTVRFAOB-XHOPJVQSSA-N
|
| InChi Code |
InChI=1S/C99H164N32O28/c1-49(2)43-62(120-82(144)64(45-54-21-10-9-11-22-54)123-88(150)68-28-18-40-129(68)94(156)60(32-34-72(103)136)118-90(152)75(51(5)6)125-89(151)70-30-19-41-130(70)93(155)59(25-15-37-112-98(107)108)117-85(147)66(48-132)124-80(142)57(31-33-71(102)135)114-78(140)55(101)46-74(138)139)81(143)122-65(47-73(104)137)83(145)121-63(44-50(3)4)84(146)126-76(52(7)133)91(153)127-77(53(8)134)95(157)131-42-20-29-69(131)86(148)115-56(24-14-36-111-97(105)106)79(141)116-58(23-12-13-35-100)92(154)128-39-17-27-67(128)87(149)119-61(96(158)159)26-16-38-113-99(109)110/h9-11,21-22,49-53,55-70,75-77,132-134H,12-20,23-48,100-101H2,1-8H3,(H2,102,135)(H2,103,136)(H2,104,137)(H,114,140)(H,115,148)(H,116,141)(H,117,147)(H,118,152)(H,119,149)(H,120,144)(H,121,145)(H,122,143)(H,123,150)(H,124,142)(H,125,151)(H,126,146)(H,127,153)(H,138,139)(H,158,159)(H4,105,106,111)(H4,107,108,112)(H4,109,110,113)/t52-,53-,55+,56+,57+,58+,59+,60+,61+,62+,63+,64+,65+,66+,67+,68+,69+,70+,75+,76+,77+/m0/s1
|
| Chemical Name |
(2R)-2-[[(2R)-1-[(2R)-6-amino-2-[[(2R)-2-[[(2R)-1-[(2R,3S)-2-[[(2R,3S)-2-[[(2R)-2-[[(2R)-4-amino-2-[[(2R)-2-[[(2R)-2-[[(2R)-1-[(2R)-5-amino-2-[[(2R)-2-[[(2R)-1-[(2R)-2-[[(2R)-2-[[(2R)-5-amino-2-[[(2R)-2-amino-3-carboxypropanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-carbamimidamidopentanoic acid
|
| Synonyms |
D-JBD19; D-JBD-19; D JBD19; 954134-42-0; D-JBD 19; orb1983777; H-D-Asp-D-Gln-D-Ser-D-Arg-D-Pro-D-Val-D-Gln-D-Pro-D-Phe-D-Leu-D-Asn-D-Leu-D-Thr-D-Thr-D-Pro-D-Arg-D-Lys-D-Pro-D-Arg-OH;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.4443 mL | 2.2217 mL | 4.4433 mL | |
| 5 mM | 0.0889 mL | 0.4443 mL | 0.8887 mL | |
| 10 mM | 0.0444 mL | 0.2222 mL | 0.4443 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
